- By ICR Secretariat
- Posted Wednesday, January 15, 2020
GSK's plan to take over the HIV drug market hasn't worked out
British drug giant GlaxoSmithKline wants to claim a larger piece of the HIV drug market. Its strategy: convince patients, doctors and insurance providers that treatments made up of two drugs are better than those made up of three.